Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broncho-Vaxom for Relapse Prevention in SSNS
NCT05044169Unknown
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
01
Overview
Randomised trial of OM-85 in nephrotic syndrome (2 arms). Primary endpoint: 1-year relapse-free survival rate. Status: unknown.
02
Drugs
OM-85
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05044169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044169.